Advertisement for orthosearch.org.uk
Results 581 - 600 of 911
Results per page:
The Bone & Joint Journal
Vol. 101-B, Issue 1 | Pages 75 - 82
1 Jan 2019
Kim J Lee SY Jung JH Kim SW Oh J Park MS Chang H Kim T

Aims

The aim of this study was to evaluate the outcome of spinal instrumentation in haemodialyzed patients with native pyogenic spondylodiscitis. Spinal instrumentation in these patients can be dangerous due to rates of complications and mortality, and biofilm formation on the instrumentation.

Patients and Methods

A total of 134 haemodialyzed patients aged more than 50 years who underwent surgical treatment for pyogenic spondylodiscitis were included in the study. Their mean age was 66.4 years (50 to 83); 66 were male (49.3%) and 68 were female (50.7%). They were divided into two groups according to whether spinal instrumentation was used or not. Propensity score matching was used to attenuate the potential selection bias. The outcome of treatment was compared between these two groups.


Bone & Joint 360
Vol. 7, Issue 2 | Pages 28 - 30
1 Apr 2018


The Bone & Joint Journal
Vol. 99-B, Issue 10 | Pages 1280 - 1285
1 Oct 2017
Jacofsky DJ

Episodic, or bundled payments, is a concept now familiar to most in the healthcare arena, but the models are often misunderstood. Under a traditional fee-for-service model, each provider bills separately for their services which creates financial incentives to maximise volumes. Under a bundled payment, a single entity, often referred to as a convener (maybe the hospital, the physician group, or a third party) assumes the risk through a payer contract for all services provided within a defined episode of care, and receives a single (bundled) payment for all services provided for that episode. The time frame around the intervention is variable, but defined in advance, as are included and excluded costs. Timing of the actual payment in a bundle may either be before the episode occurs (prospective payment model), or after the end of the episode through a reconciliation (retrospective payment model). In either case, the defined costs over the defined time frame are borne by the convener.

Cite this article: Bone Joint J 2017;99-B:1280–5.


Bone & Joint 360
Vol. 7, Issue 5 | Pages 28 - 30
1 Oct 2018


Bone & Joint 360
Vol. 6, Issue 4 | Pages 10 - 13
1 Aug 2017


Bone & Joint 360
Vol. 7, Issue 1 | Pages 12 - 14
1 Feb 2018


Bone & Joint 360
Vol. 7, Issue 4 | Pages 36 - 38
1 Aug 2018


The Bone & Joint Journal
Vol. 99-B, Issue 7 | Pages 979 - 986
1 Jul 2017
Schwab JH Janssen SJ Paulino Pereira NR Chen YLE Wain JC DeLaney TF Hornicek FJ

Aims

The aim of the study was to compare measures of the quality of life (QOL) after resection of a chordoma of the mobile spine with the national averages in the United States and to assess which factors influenced the QOL, symptoms of anxiety and depression, and coping with pain post-operatively in these patients.

Patients and Methods

A total of 48 consecutive patients who underwent resection of a primary or recurrent chordoma of the mobile spine between 2000 and 2015 were included. A total of 34 patients completed a survey at least 12 months post-operatively. The primary outcome was the EuroQol-5 Dimensions (EQ-5D-3L) questionnaire. Secondary outcomes were the Patient-Reported Outcome Measurement Information System (PROMIS) anxiety, depression and pain interference questionnaires. Data which were recorded included the indication for surgery, the region of the tumour, the number of levels resected, the status of the surgical margins, re-operations, complications, neurological deficit, length of stay in hospital and rate of re-admission.


Bone & Joint 360
Vol. 6, Issue 6 | Pages 31 - 33
1 Dec 2017


Aims

The aim of this study was to examine the efficacy and safety of multiple boluses of intravenous (IV) tranexamic acid (TXA) on the hidden blood loss (HBL) and inflammatory response following primary total hip arthroplasty (THA).

Patients and Methods

A total of 150 patients were allocated randomly to receive a single bolus of 20 mg/kg IV TXA before the incision (group A), a single bolus followed by a second bolus of 1 g IV-TXA three hours later (group B) or a single bolus followed by two boluses of 1 g IV-TXA three and six hours later (group C). All patients were treated using a standard peri-operative enhanced recovery protocol. Primary outcomes were HBL and the level of haemoglobin (Hb) as well as the levels of C-reactive protein (CRP) and interleukin-6 (IL-6) as markers of inflammation. Secondary outcomes included the length of stay in hospital and the incidence of venous thromboembolism (VTE).


Bone & Joint 360
Vol. 6, Issue 6 | Pages 17 - 20
1 Dec 2017


Bone & Joint 360
Vol. 7, Issue 3 | Pages 38 - 39
1 Jun 2018
Das A


Bone & Joint 360
Vol. 7, Issue 3 | Pages 34 - 36
1 Jun 2018


Bone & Joint 360
Vol. 5, Issue 6 | Pages 18 - 21
1 Dec 2016


Bone & Joint 360
Vol. 5, Issue 5 | Pages 2 - 7
1 Oct 2016
Forward DP Ollivere BJ Ng JWG Coughlin TA Rollins KE

Rib fracture fixation by orthopaedic and cardiothoracic surgeons has become increasingly popular for the treatment of chest injuries in trauma. The literature, though mainly limited to Level II and III evidence, shows favourable results for operative fixation. In this paper we review the literature and discuss the indications for rib fracture fixation, surgical approaches, choice of implants and the future direction for management. With the advent of NICE guidance and new British Orthopaedic Association Standards for Trauma (BOAST) guidelines in production, the management of rib fractures is going to become more and more commonplace.


Bone & Joint 360
Vol. 7, Issue 3 | Pages 14 - 16
1 Jun 2018


Bone & Joint 360
Vol. 7, Issue 3 | Pages 24 - 27
1 Jun 2018


Bone & Joint 360
Vol. 6, Issue 5 | Pages 27 - 30
1 Oct 2017


Bone & Joint 360
Vol. 7, Issue 3 | Pages 31 - 34
1 Jun 2018


Bone & Joint 360
Vol. 6, Issue 1 | Pages 24 - 26
1 Feb 2017